Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Raw Materials (2022 - 2025)

Historic Raw Materials for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Q3 2025 value amounting to $6.1 million.

  • Arcutis Biotherapeutics' Raw Materials rose 4962.09% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 million, marking a year-over-year increase of 4962.09%. This contributed to the annual value of $4.3 million for FY2024, which is 5678.83% down from last year.
  • Latest data reveals that Arcutis Biotherapeutics reported Raw Materials of $6.1 million as of Q3 2025, which was up 4962.09% from $6.7 million recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Raw Materials ranged from a high of $11.2 million in Q3 2023 and a low of $3.5 million during Q3 2022
  • In the last 4 years, Arcutis Biotherapeutics' Raw Materials had a median value of $6.5 million in 2023 and averaged $6.8 million.
  • Its Raw Materials has fluctuated over the past 5 years, first skyrocketed by 22064.13% in 2023, then tumbled by 6349.11% in 2024.
  • Arcutis Biotherapeutics' Raw Materials (Quarter) stood at $5.7 million in 2022, then soared by 75.84% to $10.0 million in 2023, then plummeted by 56.79% to $4.3 million in 2024, then surged by 42.28% to $6.1 million in 2025.
  • Its Raw Materials stands at $6.1 million for Q3 2025, versus $6.7 million for Q2 2025 and $7.6 million for Q1 2025.